C-23-substituted mycaminosyltylonolide compounds, pharmaceutical

Details C-23-substituted mycaminosyltylonolide compounds, pharmaceutical C-23-substituted mycaminosyltylonolide compounds, pharmaceutical

1985-01-18

1986-08-05

Brown, Johnnie R.

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

536 71, A61K 3171, C07H 1708

Patent

active

046043802

ABSTRACT:
C-23-bicyclic or tricyclic amino derivatives of OMT and 4'-deoxy-OMT, and pharmaceutical compositions comprising and methods of treating infections with these compounds, are provided.

REFERENCES:
patent: 4436729 (1984-03-01), Ganguly et al.
patent: 4438109 (1984-03-01), Umezawa et al.
patent: 4454314 (1984-06-01), Nagel
patent: 4459290 (1984-07-01), Kirst et al.
patent: 4463171 (1984-07-01), Umezawa et al.
patent: 4468511 (1984-08-01), Kirst et al.
patent: 4477443 (1984-10-01), Umezawa et al.
patent: 4490524 (1984-12-01), Fujiwara et al.
A. Tanaka et al., "Synthesis of 23-Dialkylamino Derivatives of Mycaminosyl Tylonolide and 4'-Deoxymycaminosyl Tylonolide Effective Against Gram-Negative Bacteria", J. Antibiotics, 35 (1) 113-116 (1982).
S. Sakamoto et al., "Synthesis of 23-Deoxy-23-N-ethyl-23-(2-fluoro-, 2,2-difluoro-, and 2,2,2-trifluoroethyl)amino Derivatives of Mycaminosyl Tylonolide and 4'-Deoxymycaminosyl Tylonolide", J. Antibiotics, 37 (12), 1628-1634 (1984).
M. Debono et al., copending U.S. application Ser. No. 614,343, filed May 25, 1984 entitled "C-20- and C-23-Modified Macrolide Derivatives", which is a continuation-in-part of application Ser. No. 470,833, filed Feb. 28, 1983.

Affiliated with

Also associated with

Rating

C-23-substituted mycaminosyltylonolide compounds, pharmaceutical does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with C-23-substituted mycaminosyltylonolide compounds, pharmaceutical, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and C-23-substituted mycaminosyltylonolide compounds, pharmaceutical will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-969170